UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $60.00 price target on the stock.

A number of other brokerages have also recently weighed in on URGN. Oppenheimer raised their target price on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an outperform rating in a report on Friday, June 14th. LADENBURG THALM/SH SH upped their price objective on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a buy rating in a research note on Friday, June 14th. Finally, Guggenheim began coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a buy rating and a $40.00 price target on the stock.

UroGen Pharma Trading Up 2.6 %

Shares of NASDAQ URGN opened at $12.70 on Thursday. UroGen Pharma has a 12-month low of $10.60 and a 12-month high of $20.70. The company has a market cap of $297.87 million, a price-to-earnings ratio of -3.74 and a beta of 1.11. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The stock’s 50 day simple moving average is $14.04 and its 200 day simple moving average is $14.53.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million during the quarter, compared to the consensus estimate of $23.69 million. Equities research analysts expect that UroGen Pharma will post -3.49 EPS for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Point72 Asset Management L.P. raised its stake in shares of UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares in the last quarter. Millennium Management LLC raised its holdings in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares in the last quarter. RTW Investments LP boosted its stake in UroGen Pharma by 101.4% during the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after buying an additional 869,344 shares in the last quarter. Cowen AND Company LLC lifted its stake in UroGen Pharma by 29.1% during the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock worth $35,229,000 after purchasing an additional 472,893 shares during the period. Finally, Great Point Partners LLC grew its position in UroGen Pharma by 10.9% in the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after acquiring an additional 285,714 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.